Correlation Between De Licacy and Medigen Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both De Licacy and Medigen Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining De Licacy and Medigen Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between De Licacy Industrial and Medigen Biotechnology, you can compare the effects of market volatilities on De Licacy and Medigen Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in De Licacy with a short position of Medigen Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of De Licacy and Medigen Biotechnology.

Diversification Opportunities for De Licacy and Medigen Biotechnology

-0.15
  Correlation Coefficient

Good diversification

The 3 months correlation between 1464 and Medigen is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding De Licacy Industrial and Medigen Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medigen Biotechnology and De Licacy is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on De Licacy Industrial are associated (or correlated) with Medigen Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medigen Biotechnology has no effect on the direction of De Licacy i.e., De Licacy and Medigen Biotechnology go up and down completely randomly.

Pair Corralation between De Licacy and Medigen Biotechnology

Assuming the 90 days trading horizon De Licacy Industrial is expected to generate 1.36 times more return on investment than Medigen Biotechnology. However, De Licacy is 1.36 times more volatile than Medigen Biotechnology. It trades about -0.05 of its potential returns per unit of risk. Medigen Biotechnology is currently generating about -0.14 per unit of risk. If you would invest  1,720  in De Licacy Industrial on October 10, 2024 and sell it today you would lose (55.00) from holding De Licacy Industrial or give up 3.2% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

De Licacy Industrial  vs.  Medigen Biotechnology

 Performance 
       Timeline  
De Licacy Industrial 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in De Licacy Industrial are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, De Licacy may actually be approaching a critical reversion point that can send shares even higher in February 2025.
Medigen Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Medigen Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

De Licacy and Medigen Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with De Licacy and Medigen Biotechnology

The main advantage of trading using opposite De Licacy and Medigen Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if De Licacy position performs unexpectedly, Medigen Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Biotechnology will offset losses from the drop in Medigen Biotechnology's long position.
The idea behind De Licacy Industrial and Medigen Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Complementary Tools

Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk